Day: February 23, 2023

FDA Approves Sanofi’s Once-Weekly ALTUVIIIO™

Source: Sanofi Press Release Sanofi announces that the U.S. Food and Drug Administration approved ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-vWF-XTEN Fusion Protein-ehtl], previously known as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy for adults and children with hemophilia A.  Sanofi states that with ALTUVIIIO, they are looking to raise the bar for people with […]